TSH (thyroid-stimulating hormone) is the "command hormone" determining how actively the thyroid works. Secreted by the pituitary gland in the brain, it directs production of thyroid hormones (T3 and T4). These directly affect metabolic rate, weight balance, heart rhythm, temperature regulation, bowel movements, and mood.

Fatigue, weight gain or loss, palpitations, sleep disturbances, constipation, and diarrhea are common in cancer patients and often attributed to "the cancer itself" or "chemotherapy." Yet many of these complaints may stem from thyroid dysfunction and TSH is generally the first test to reveal it.

In particular, commonly used modern treatments such as immunotherapies, certain tyrosine kinase inhibitors (TKIs) and head and neck/mediastinal radiotherapy may affect the thyroid. Thyroid or pituitary surgery, radioiodine, and some older immunomodulators may also permanently alter TSH and thyroid function tests.

TSH Physiology and Basic Concepts

TSH (thyroid stimulating hormone) is the main regulatory hormone secreted by the anterior pituitary, controlling thyroid production of T4 (thyroxine) and T3 (triiodothyronine) . The hypothalamic–pituitary–thyroid axis operates through negative feedback:

Free T4/T3 falls → pituitary TSH production increases.
Free T4/T3 rises → TSH production is suppressed.

Practical point: TSH is highly sensitive and often detects thyroid dysfunction earlier than free T4. However, with suspected central (pituitary/hypothalamic) disease , TSH alone is insufficient and must be interpreted with fT4.

Although laboratory-dependent, a commonly used adult reference range is approximately 0.4–4.0 mIU/L. Pregnancy, older age, and severe systemic illness may affect its interpretation.

High TSH — Tendency Toward Hypothyroidism

High TSH usually reflects an underactive thyroid (primary hypothyroidism). The pituitary secretes more TSH to compensate for falling circulating T4/T3.

High TSH + low fT4 → Overt hypothyroidism
High TSH + normal fT4 → Subclinical hypothyroidism

Common causes include Hashimoto thyroiditis, iodine deficiency, thyroid surgery, radioiodine, and certain drugs. In cancer patients, targeted therapies, older immunomodulators such as interferon, and radiation-induced thyroid injury may particularly cause high TSH.

A caution for oncology practice: avoid a permanent diagnosis based on one TSH result; severe coexisting illness, steroid use, radiocontrast exposure, and acute-phase responses may temporarily disrupt thyroid tests, particularly in cancer patients.

Low TSH — Tendency Toward Hyperthyroidism and Other Causes

Low TSH generally indicates excess thyroid hormone (hyperthyroidism/thyrotoxicosis). It may also occur in intensive care, severe systemic illness, and pituitary failure.

Low TSH + high fT4/fT3 → Primary hyperthyroidism
Low TSH + normal fT4/fT3 → Subclinical hyperthyroidism or nonthyroidal illness

In cancer patients, immune-related destructive thyroiditis, early TKI-related changes, radiation-induced thyroiditis, or incorrect/excessive L-thyroxine replacement may lower TSH.

The Clinical Importance of TSH in Cancer Patients

Thyroid dysfunction is common in cancer patients due both to primary thyroid diseaseand secondary effects of cancer treatments . Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4), TKIs, head and neck/mediastinal radiotherapy, and thyroid/pituitary surgery make TSH monitoring particularly critical.

Main goals:

immunotherapy- and TKI-related thyroid dysfunction should be detected early,
After head and neck radiotherapy or thyroid surgery, late hypothyroidism should be identified,
Symptoms such as fatigue, weight change, palpitations, and psychiatric problems require clarification of nonspecific complaints,
After thyroid cancer, the TSH suppression target should be adjusted according to recurrence risk.

Which Cancer Treatments Require Routine TSH Monitoring?

Treatment / Situation	Recommended TSH Monitoring Frequency	Brief Note
Immune checkpoint inhibitors (PD-1 / PD-L1 / CTLA-4)	Baseline TSH + fT4, then during the first 6–12 months, every 4–6 weeks (or before each cycle); then every 3 months	Thyroid irAEs are the most common endocrine toxicity; rates may reach 10–30%, up to 40% in some series.
VEGFR/multitargeted TKIs (particularly sunitinib, sorafenib, pazopanib, etc.)	Baseline TSH + fT4; for the first 6 months, every 4–8 weeks; every 3–6 months once stable	Hypothyroidism incidence varies by series, 30–80%; more commonly reported with sunitinib.
Head and neck, mediastinal, or upper thoracic radiotherapy	Pretreatment baseline; at 6–12 months in the first year after radiotherapy, then every 6–12 months for long-term follow-up	Radiation-induced hypothyroidism may develop over years; NCCN and head and neck survivorship recommendations follow this approach.
Thyroid surgery (total thyroidectomy) ± radioiodine	Every 6–8 weeks during L-thyroxine adjustment; at least 1 time annually on a stable dose	According to thyroid cancer recurrence risk, maintain TSH in a suppressed/normal range.
Pituitary surgery / pituitary radiosurgery	Early postoperatively; then every 6–12 months (with fT4 to assess central hypothyroidism)	Low fT4 may indicate central hypothyroidism even with normal or low-normal TSH.
Stem cell transplantation, interferon, older immunomodulators such as IL-2	Baseline and annually; more often if clinically suspected	Autoimmune thyroiditis and late hypothyroidism may develop.

Practical recommendation: in all immunotherapy and TKI patients, checking baseline TSH + fT4 and continuing regular checks throughout treatment greatly assists both symptom interpretation and dose/treatment modification.

Immunotherapy-Related Thyroid Dysfunction and TSH

Among endocrine adverse effects, immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) most commonly cause thyroid dysfunction. Toxicity may follow a thyroiditis pattern of transient thyrotoxicosis followed by hypothyroidism.

Monitoring: When Should TSH Be Tested?

Immunotherapy: before starting, baseline TSH + fT4 (± fT3, anti-TPO),
During the first 6–12 months, every 4–6 weeks (or before each cycle), TSH + fT4,
Every 3 months in stable patients on prolonged treatment; monitoring for at least 6–12 months after discontinuation is also recommended.

High TSH (hypothyroidism after immunotherapy):

rising TSH with falling fT4 after immunotherapy often indicates primary hypothyroidism (autoimmune thyroiditis). Most cases are mild to moderate and managed with L-thyroxine replacement ; immunotherapy is generally not discontinued, only temporarily withheld for severe symptoms.

Low TSH (thyrotoxicosis after immunotherapy):

suppressed TSH with raised fT4/fT3 during early treatment usually indicates transient thyrotoxicosis due to destructive thyroiditis. Beta-blockers and symptomatic support often suffice; antithyroid drugs are generally unnecessary.

Important nuance: hypothyroidism developing during immunotherapy is usually permanent and requires TSH-based long-term monitoring even after treatment; current studies and guidelines particularly emphasize this.

Tyrosine Kinase Inhibitors and TSH Monitoring

Multitargeted TKIs, particularly those targeting VEGFR (sunitinib, sorafenib, pazopanib, etc.), may cause high rates of thyroid dysfunctionin cancer patients. Various series reported hypothyroidism incidences of 30–80% with sunitinib.

Possible mechanisms

Reduced thyroid vascular supply and ischemic atrophy,
Inhibition of thyroid peroxidase activity,
Impaired iodine uptake and hormone synthesis,
Effects triggering autoimmunity.

Monitoring recommendation: TSH + fT4 before starting a TKI, then during the first 6 months, every 4–8 weeks, followed by TSH every 3–6 months; L-thyroxine replacement for hypothyroidism generally does not prevent continuation of TKI therapy.

Some studies associated hypothyroidism, particularly with sunitinib, with better progression-free survival. Hypothyroidism alone should therefore not justify stopping treatment; it should be managed with regular TSH monitoring and replacement.

TSH After Head and Neck Radiotherapy, Thyroid Surgery, and in Survivorship

Head and neck/mediastinal radiotherapy

Radiotherapy for head and neck cancers or Hodgkin lymphoma may cause radiation-induced hypothyroidism over the years. NCCN and survivorship guidelines recommend TSH monitoring every 6–12 months in these patients.

Thyroid surgery and/or radioiodine

After total thyroidectomy +/– radioiodine for thyroid cancer, TSH is the key parameter for adjusting L-thyroxine dosing and the target TSH range to clinical risk:

Low-risk differentiated thyroid cancer: generally maintain TSH 0.5–2 mIU/L as the range.
High recurrence risk: in the early years, a suppression target of TSH 0.1–0.5 mIU/L (or even lower) may be considered.

Risk–benefit balance: excessive TSH suppression increases the risk of osteoporosis and atrial fibrillation , particularly in postmenopausal women. Suppression should therefore be individualized according to age, cardiovascular condition, and recurrence risk.

Interpreting TSH in a Cancer Patient

Step 1 – Establish the clinical context

Which cancer type? Which stage?
Treatments received: immunotherapy, TKIs, head and neck/mediastinal radiotherapy, thyroid/pituitary surgery?
Symptoms: fatigue, weight change, palpitations, heat intolerance, GI complaints, depressed mood?

Step 2 – Always request fT4 (and fT3 if needed) alongside TSH

High TSH + low fT4 → Primary hypothyroidism → plan replacement.
Low TSH + high fT4 → Hyperthyroidism/thyrotoxicosis → manage according to cause (destructive thyroiditis vs. Graves).
Normal/low TSH + low fT4 → Central hypothyroidism must not be ruled out (especially with pituitary disease/radiotherapy history).

Critical warning: in a cancer patient, central hypothyroidism does not always present with high TSH; pituitary failure may produce normal or low-normal TSH. Therefore, relying on TSH alone is risky; always assess fT4 together with it.

TSH is among the most sensitive indicators of thyroid function; regular monitoring in oncology is particularly needed with immunotherapy, TKIs, and head and neck/mediastinal radiotherapy treatment.
Thyroid dysfunction is the most common endocrine immune-related adverse effect of checkpoint inhibitors; monitoring TSH and fT4 every 4–6 weeks enables early diagnosis before symptoms develop.
TKI-related hypothyroidism, although common, is generally easily managed with replacement and has been associated with better prognosis in some series.
Radiation-induced hypothyroidism after head and neck radiotherapy may develop late, so TSH monitoring is recommended every 6–12 months for years afterward.
TSH in cancer patients should always be interpreted alongside fT4 (and fT3 when needed) with central hypothyroidism kept in mind.

Clinical rule: For unexplained fatigue, weight change, palpitations, heat intolerance, or mood changes in a cancer patient, reviewing the latest TSH/fT4 results and cancer treatments is often the most practical step toward diagnosis.

References

Schneider BJ et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. J Clin Oncol. 2021.
Yamauchi I et al. Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors. Eur Thyroid J. 2025.
Muir CA et al. Immune Related Adverse Events of the Thyroid. Front Endocrinol. 2022.
Chera A et al. Thyroid-related adverse events induced by immune checkpoint inhibitors. 2022.
El Sabbagh R et al. Thyroid dysfunctions due to immune checkpoint inhibitors: a review. Int J Gen Med. 2020.
Nowicka Z et al. Radiation-Induced Hypothyroidism in Patients with Head and Neck Cancer. 2020.
Goyal N et al. Head and neck cancer survivorship consensus statement. 2022.
Funakoshi T et al. Risk of hypothyroidism in patients with cancer treated with sunitinib: a meta-analysis. 2013.
Buda-Nowak A et al. Sunitinib-induced hypothyroidism and outcomes in metastatic RCC. 2017.
NCCN Guidelines & Survivorship Principles – Sections on thyroid and endocrine late effects.

Menu